Schizophrenia/Psychosis

The medication treatment of schizophrenia has finally diversified to a novel neurotransmitter system: the muscarinic cholinergic system.

The authors of the Clinician's Corner column discuss the latest FDA-approved treatment for schizophrenia.

New positive results demonstrate the efficacy and safety of lumateperone (Caplyta) 42 mg for the prevention of relapse in adult patients with schizophrenia.

A new collaboration to address sleep disturbances associated with cognitive impairment, an unmet need.

Posters from Psych Congress confirm the durability of long-term treatment with xanomeline/trospium (Cobenfy).

Here's what you need to know about the latest FDA-approved schizophrenia treatment.

Check out this unique approach to foster positive and trusting relationships via natural interactions in the community and minimize the stigma related to psychosis.

Postpartum psychosis has a complicated presentation and is often misdiagnosed or missed in patients.

The first episode of schizophrenia is a critical period of illness.

Learn more about the new positive efficacy, safety, tolerability data from the phase 3 SOLARIS trial, which were presented at the 37th Annual European College of Neuropsychopharmacology Congress.

New data shared at ECNP Congress informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of Perseris to risperidone (Uzedy).

Jelena Kunovac, MD, MS, discusses last week's approval of Cobenfy, an agent with a novel mechanism of action that could revolutionize schizophrenia treatment.

After 30+ years of clinical experience with clozapine, it is time for professional psychiatry to demand an end to this discriminatory clozapine REMS program.

The vice president of Clinical Development and Medical Affairs, Mental Health at Boehringer Ingelheim shares why it is such an unprecedented moment for schizophrenia research.

Cobenfy: Only the first in a new upcoming class of antipsychotics.

While there is still a lot to learn about Cobenfy, here's why it marks a historic moment in the treatment of schizophrenia.

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.

The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?

Does reduced blood monitoring impact the detection of hematological abnormalities in clozapine-treated patients? Researchers performed a chart review study from the COVID-10 pandemic.

The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.

New data informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of RBP-7000 (Perseris) to risperidone (Uzedy), an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults.

Check out new positive efficacy, safety, and tolerability results from the phase 3 SOLARIS trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia.

How comfortable do you feel in your knowledge of this type of treatment?

Later this month, the FDA will vote on KarXT, a novel muscarinic acetylcholine receptor agonist.

Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment?

Assisted outpatient treatment is not intended to replace comprehensive, easy-to-access, voluntary treatment. Here's why we need it, according to one expert.

The PDUFA date for KarXT for schizophrenia is September 26, 2024. Here’s what one expert thinks of this potential treatment.

A new study of adult emergency department admissions found that individuals taking high doses of amphetamine—like Adderall—have a 5-fold increased risk for developing psychosis or mania.

Neurosyphilis may occur during any stage of syphilis. Learn more about this diagnosis via case study example here.

Antidepressants posed "negligible" risk of inducing mania in bipolar depression, in a target trial emulation with a larger cohort than in RCTs that have assessed this effect.